Learn More
Genscript Corporation CLEC12A/MICL/CLL-1 hFc Chimera
Supplier: Genscript Corporation Z03958100

CLEC12A has recently been identified as an antigen expressed on leukemic stem cells and leukemic blasts Given the fact that this expression profile seems stable throughout diagnosis treatment and relapse on leukemic blasts and leukemic stem cells CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.